43.81

9.80% 3.91

After Hours: 43.87 0.06 +0.14%

Oruka Therapeutics Inc (ORKA)

Overview News Price History Discussions Forecast

Oruka Therapeutics Inc stock is traded at $43.81, with a volume of 811.97K. It is up +9.80% in the last 24 hours and up +24.18% over the past month. Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.

Previous Close:

$39.90

Open:

$40.18

24h Volume:

811.97K

Relative Volume:

1.43

Market Cap:

$2.17B

Revenue:

Net Income/Loss:

$-105.43M

P/E Ratio:

-18.90

EPS:

-2.3183

Net Cash Flow:

$-88.42M

1W Performance:

+7.38%

1M Performance:

+24.18%

6M Performance:

+191.10%

1Y Performance:

+265.39%

1-Day Range:

$39.84

$45.52

1-Week Range:

$37.55

$45.52

52-Week Range:

$5.485

$45.52

Oruka Therapeutics Inc Stock (ORKA) Company Profile

Name

Oruka Therapeutics Inc

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

650-606-7910

Address

855 OAK GROVE AVE., MENLO PARK

Employee

Twitter

Next Earnings Date

2026-03-12

Latest SEC Filings

ORKA's Discussions on Twitter

Compare ORKA vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ORKA Oruka Therapeutics Inc	43.81	1.98B	0	-105.43M	-88.42M	-2.3183
VRTX Vertex Pharmaceuticals Inc	454.97	113.96B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	78.41B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	40.85B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	42.05B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	29.99B	606.42M	-1.28B	-997.58M	-6.403

Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-18-25	Initiated	Piper Sandler	Overweight
Nov-13-25	Initiated	Jefferies	Buy
Oct-27-25	Initiated	Guggenheim	Buy
Oct-13-25	Initiated	Barclays	Overweight
May-22-25	Initiated	BTIG Research	Buy
Feb-04-25	Initiated	Wolfe Research	Outperform
Oct-11-24	Initiated	Stifel	Buy
Oct-07-24	Initiated	H.C. Wainwright	Buy
Sep-17-24	Initiated	Leerink Partners	Outperform
Sep-16-24	Initiated	TD Cowen	Buy
Sep-13-24	Initiated	Jefferies	Buy
Feb-27-18	Initiated	Ascendiant Capital Markets	Buy
Oct-09-13	Initiated	Dawson James	Buy

View All

Oruka Therapeutics Inc Stock (ORKA) Latest News

12:03 PM

Oruka Therapeutics (NASDAQ:ORKA) Hits New 12-Month HighShould You Buy? - MarketBeat

12:03 PM

09:52 AM

Oruka Therapeutics stock hits 52-week high at 43.0 USD - Investing.com

09:52 AM

01:48 AM

Aug Selloffs: Will Oruka Therapeutics Inc outperform tech stocksQuarterly Investment Review & AI Powered Market Entry Strategies - baoquankhu1.vn

01:48 AM

Mar 24, 2026

Does Oruka’s Widening Loss and ESOP Shelf Registration Change The Bull Case For Oruka Therapeutics (ORKA)? - Yahoo Finance Singapore

Mar 24, 2026

Piper Sandler reiterates Oruka Therapeutics stock rating at Overweight By Investing.com - Investing.com Canada

Mar 24, 2026

Mar 22, 2026

Oruka Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | | US6876041087 - marketscreener.com

Mar 22, 2026

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Mar 22, 2026

Mar 20, 2026

Oruka Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | HQ1 | US6876041087 - marketscreener.com

Mar 20, 2026

Mar 19, 2026

Oruka Therapeutics (NASDAQ:ORKA) Sets New 52-Week HighStill a Buy? - MarketBeat

Mar 19, 2026

Does Oruka Therapeutics, Inc. (ORKA) have the potential to rally 41.51% as Wall Street analysts expect? - MSN

Mar 19, 2026

Mar 17, 2026

BTIG Reiterates Oruka Therapeutics (ORKA) Buy Recommendation - MSN

Mar 17, 2026

Oruka Therapeutics (ORKA) chief medical officer sells $313k in stock By Investing.com - Investing.com India

Mar 17, 2026

Oruka Therapeutics (NASDAQ:ORKA) SVP Sells $16,313.50 in Stock - MarketBeat

Mar 17, 2026

Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) Insider Sells 7,641 Shares of Stock - MarketBeat

Mar 17, 2026

Oruka Therapeutics (ORKA) chief medical officer sells $313k in stock - Investing.com

Mar 17, 2026

Oruka Therapeutics (NASDAQ:ORKA) CEO Sells $71,407.70 in Stock - MarketBeat

Mar 17, 2026

Agarwal Arjun, Oruka Therapeutics SVP, sells $16k in ORKA stock - Investing.com Canada

Mar 17, 2026

[Form 4] Oruka Therapeutics, Inc. Insider Trading Activity - Stock Titan

Mar 17, 2026

Does Oruka Therapeutics, Inc. (ORKA) Have a Chance to Surge 41.51% According to Wall Street Analysts’ Predictions? - Bitget

Mar 17, 2026

Does Oruka Therapeutics, Inc. (ORKA) Have the Potential to Rally 41.51% as Wall Street Analysts Expect? - Yahoo Finance

Mar 17, 2026

Oruka Therapeutics (NASDAQ:ORKA) Price Target Raised to $86.00 at Leerink Partners - Defense World

Mar 17, 2026

Mar 16, 2026

Is Oruka Therapeutics’ (ORKA) ESOP Shelf Registration Quietly Redefining Its Funding Playbook? - simplywall.st

Mar 16, 2026

Oruka Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 16, 2026